or
forgot password

    • cancer clinical trials in hamden, CT

    • FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer
    Medical Oncology & Hematology PC
    Hamden, Connecticut
    Gastroesophageal Cancer, Gastric Cancer
    Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis
    Gastroenterology Center of Connecticut, LLC

    Trial Locations
    Gastroenterology Center of Connecticut, LLC
    Medical Research Center of Connecticut, LLC
    Ulcerative Colitis
    Gemcitabine With or Without Exatecan Mesylate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
    Medical Oncology and Hematology, P.C.
    Hamden, Connecticut 06518
    Pancreatic Cancer
    HORIZON-PFT: Pivotal Fracture Trial
    Northeast Clinical Research
    Hamden, Connecticut 06518-3272
    Osteoporosis
    Soblidotin in Treating Patients With Progressive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    Medical Oncology and Hematology, P.C.
    Hamden, Connecticut 06518
    Lung Cancer
    Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)
    Local Institution
    Hamden, Connecticut
    Breast Cancer, Metastases
    Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    Medical Oncology & Hematology, P. C.
    Hamden, Connecticut 06518
    Non Small Cell Lung Carcinoma
    STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma
    Medical Oncology and Hematology, P.C.
    Hamden, Connecticut 06518
    Melanoma
    Study of BMS-275183 in Patients With Pre-treated Non-small Cell Lung Cancer
    Local Institution
    Hamden, Connecticut
    Non-small Cell Lung Cancer
    Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium
    Local Institution
    Hamden, Connecticut
    Transitional Cell Carcinoma, Bladder Neoplasms, Kidney Neoplasms, Ureter Neoplasms, Bladder Cancer, Neoplasm, Bladder
    Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib
    Local Institution
    Hamden, Connecticut
    Chronic Myeloid Leukemia, Philadelphia-Positive Myeloid Leukemia
    Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia
    Local Institution
    Hamden, Connecticut
    Chronic Myeloid Leukemia, Philadelphia-Positive Myeloid Leukemia
    A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate
    Local Institution
    Hamden, Connecticut
    Leukemia, Myeloid, Chronic, Leukemia, Lymphocytic, Acute, L2
    Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Active Ulcerative Colitis
    Site Ref # / Investigator 3754
    Hamden, Connecticut 06518
    Ulcerative Colitis
    Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma
    New England Retina Associates
    Hamden, Connecticut 06518
    Choroidal Melanoma
    Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
    Gastroenterology Center of Connecticut, P.C.
    Hamden, Connecticut 06518
    Crohn's Disease
    Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis
    Gastroenterology Center of Connecticut, P.C.
    Hamden, Connecticut 06518
    Ulcerative Colitis
    Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma
    Local Institution
    Hamden, Connecticut
    Melanoma
    Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
    Gastroenterology Center of Connecticut P.C.
    Hamden, Connecticut 65180
    Crohn's Disease
    Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)
    New England Retina Associates
    Hamden, Connecticut 06518
    Choroidal Melanoma